ESR1 and prostate carcinoma: However, in a few cancers—notably luminal breast and prostate cancer—ChIP-seq analyses of key transcriptional regulators, estrogen receptor (ER), and androgen receptor (AR) respectively, in both cell line models5,6 and tumors7,8 have revealed the importance of enhancers distal to gene promoters in gene regulatory programs.